And my response to Matt on SA.... Matt- I thin
Post# of 56323
Matt-
I think you're smarter than this as you are letting your personal issues with the company drive an article that is over-reaching in its speculation and attempt to cast further doubt to impact the share price negatively.
I think you can easily understand that FITX is doing what they can to create a separate company focused on MMJ/Hemp and take the opportunity to address the share structure as they have been consistently beat-up in this regard.
I fully expect more details to be provided shortly and guidance as to a much smaller share structure (Tweed, Bedrocan and OrganiGram have an average of ~50M shares I believe) and target pricing of both existing FITX and the newly created company.
If you don't have the foresight to see this, then you shouldn't be writing business posts. If you do understand what the company is attempting to do and continue to write such articles to take advantage of initial ambiguity, then it's a pretty clear indictment of your character. In either case, you're better than this.
Regards,
-kbulldog.